Results 91 to 100 of about 6,033 (189)

Irinotecan pathway genotype analysis to predict pharmacokinetics [PDF]

, 2003
PURPOSE: The purpose was to explore the relationships between irinotecan disposition and allelic variants of genes coding for adenosine triphosphate binding cassette transporters and enzymes of putative relevance for irinotecan ...
Baker, S.D. (Sharyn), Karlsson, M.O., Marsh, S. (Steven), Mathijssen, A.H.J. (Ron), McLeod, H.L. (Howard), Sparreboom, A. (Alex), Verweij, J. (Jaap), Xie, R. (Rujia)   +7 more
core  

GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA

Российский кардиологический журнал, 2015
Antiplatelet therapy is one of the most importance in therapy of patients with injured coronary, cerebral and peripheral arteries. The standard of acute coronary syndrome patients treatment is double antiplatelet therapy: acetylsalicylic acid with ...
K. B. Mirzaev, D. A. Sychev, D. A. Andreev   +2 more
doaj   +1 more source

A Novel 10‐Protein Score for Liver Fat Content Predicts Cardiovascular‐Kidney‐Metabolic Disease Risk

Advanced Science, Volume 13, Issue 10, 18 February 2026.
A novel 10‐protein plasma score precisely quantifies liver fat, outperforming the fatty liver index. It robustly predicts the risk of numerous cardiovascular‐kidney‐metabolic diseases and integrates with genetic data for precision prevention, offering a practical alternative to magnetic resonance imaging (MRI). Abstract Liver fat content (LFC) is a key
Xiaoqin Gan, Yuanxiu Wei, Yiting Wu, Xinyue Su, Gangling Wang, Sisi Yang, Ziliang Ye, Yanjun Zhang, Hao Xiang, Yu Huang, Yiwei Zhang, Yuanyuan Zhang, Xianhui Qin   +12 more
wiley   +1 more source

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects

Pharmaceutics
Hepatic carboxylesterase 1 (CES1) metabolizes numerous prodrugs into active ingredients or direct-acting drugs into inactive metabolites. We aimed to develop a semi-physiologically based pharmacokinetic (semi-PBPK) model to simultaneously predict the ...
Xin Luo, Zexin Zhang, Ruijing Mu, Guangyu Hu, Li Liu, Xiaodong Liu   +5 more
doaj   +1 more source

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA

Рациональная фармакотерапия в кардиологии, 2015
The clinical significance of the patient genetic characteristics in the individual pharmacological response to oral anticoagulants is considered. Possible tactics of warfarin dosing and new oral anticoagulants choice on the basis of pharmacogenetic ...
D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev   +3 more
doaj   +1 more source

A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC)

Molecules, 2020
Gemcitabine (dFdC) demonstrates significant effectiveness against solid tumors in vitro and in vivo; however, its clinical application is limited because it tends to easily undergo deamination metabolism.
Yilin Sun, Jiankun Wang, Kun Hao
doaj   +1 more source

Specific heat of Ba$_{0.59}$K$_{0.41}$Fe$_{2}$As$_{2}$, and a new method for identifying the electron contribution: two electron bands with different energy gaps in the superconducting state

, 2015
We report measurements of the specific heat of Ba$_{0.59}$K$_{0.41}$Fe$_{2}$As$_{2}$, an Fe-pnictide superconductor with $T_c$ = 36.9 K, for which there are suggestions of an unusual electron pairing mechanism. We use a new method of analysis of the data
Birgeneau, R. J., Forrest, T. R., Phillips, N. E., Rotundu, C. R.   +3 more
core   +1 more source

Gut Bacterium Lysinibacillus Sphaericus Exacerbates Aspirin‐induced Intestinal Injury by Production of Carboxylesterase EstB

Advanced Science, Volume 13, Issue 12, 27 February 2026.
Schematic overview illustrating the detrimental role of gut microbiota in aspirin‐induced intestinal injury. L. sphaericus and its secreted carboxylesterase EstB are identified as key drivers that catalyze aspirin hydrolysis into salicylic acid, thereby exacerbating intestinal injury. Inhibition of EstB by the dietary compound flavanomarein effectively
Zeyu Zhao, Qing Li, Xiaowu Bai, Ertao Zhai, Weigang Dai, Yan Qian, Tianhao Zhang, Zhixin Huang, Ziyu Huang, Fangang Meng, Jianhui Chen, Tao Zuo, Shirong Cai, Risheng Zhao   +13 more
wiley   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients

Scientific Reports, 2017
Carboxylesterase 1 (CES1) hydrolyzes the prodrug clopidogrel to an inactive carboxylic acid metabolite. The effects of CES1 S75N (rs2307240,C>T) on clopidogrel response among 851 acute coronary syndrome patients who came from the north, central and south
Fei-Yan Xiao, Jian-Quan Luo, Min Liu, Bi-Lian Chen, Shan Cao, Zhao-Qian Liu, Hong-Hao Zhou, Gan Zhou, Wei Zhang   +8 more
doaj   +1 more source